Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder

Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder

BACKGROUND

Depression and obesity are debilitating conditions representing an enormous health and economic burden worldwide. Depression is common among patients with excess weight, but more importantly, these patients may be at risk for poor response when treated with antidepressant medications (AD).

METHODS

We conducted a comprehensive scoping review to summarize the evidence regarding the difference in response to treatment of depression with AD among patients with excess weight as compared to normal weight patients and to identify knowledge gaps.

RESULTS

The search of the Medline and PsycINFO (2004-2019) identified twelve relevant studies. Tabulation and frequency analysis of the charted data along with a narrative synthesis were performed. Nine studies (75%) reported clinically relevant negative association between patients' high BMI or obesity and treatment response to either nortriptyline, fluoxetine, or various AD; one study (8.3%) reported no difference in response to various AD combinations between BMI groups. One study showed benefits of bupropion and escitalopram combination in patients with morbid obesity (BMI > 35 kg/m²) as compared with escitalopram monotherapy. Another study reported benefits when using venlafaxine-XR in patients with morbid obesity. We also acknowledge the possible role of sex and genetic factors predicting AD treatment response.

LIMITATIONS

The search was restricted to two most relevant sources, publications in four languages and adult population.

CONCLUSION

The synthesized data may be useful to physicians in their decision regarding the choice of AD in patients with excess weight. Researchers need to address causality of association between obesity and treatment response to individual AD types.

Association between subclinical hypothyroidism and metabolic syndrome among individuals with depression

BACKGROUND

Although the connection among low thyroid function, metabolic abnormalities, and depression is well documented, the relationship between subclinical hypothyroidism (SCH) and metabolic syndrome (MetS) in depression remains unclear. This study examined the association between SCH and MetS in a large sample with depression.

METHODS

The study analyzed 370 individuals with depression who participated in the 2014 Korea National Health and Nutrition Examination Survey. Associations between the presence of SCH and MetS were estimated after adjusting for related factors using multivariate logistic regression analysis.

RESULTS

In the 370 individuals with depression, the prevalence of SCH was 9.4% (SE = 1.6%). The prevalence of MetS was significantly higher in depressed individuals with than in those without SCH (56.3 ± 9.5% vs. 22.8 ± 2.6%; p = 0.001). After adjusting for covariates, the odds of having MetS were 7.127 times greater among depressed individuals with SCH than among those without SCH (95% confidence interval, 2.077-24.458).

LIMITATIONS

The cross-sectional study design prevented inferences regarding causality and the effects of changes in variables.

CONCLUSIONS

Depressed individuals with SCH are more likely to meet the criteria for MetS. These results highlight the significance of low thyroid function and the metabolic burden of individuals with depression.

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline

PURPOSE

This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder.

METHODS

Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18-40 years, >40 to <55 years, 55-<65 years, and ≥65 years) and baseline depression severity (mild, 17-item Hamilton Rating Scale for Depression total score [HAM-D17] ≤18; moderate, HAM-D17 >18 to <25; severe, HAM-D17 ≥25) on desvenlafaxine efficacy were assessed using analysis of covariance for continuous end points and logistic regression for categorical end points.

FINDINGS

Desvenlafaxine-treated (50 or 100 mg/d) patients had significantly (P < 0.05, 2-sided) greater improvement in most measures of depression and function compared with placebo for patients 18 to 40 years, older than 40 to younger than 55 years, and 55 to younger than 65 years, with no significant evidence of an effect of age. Desvenlafaxine significantly improved most measures of depression and function in moderately and severely depressed patients. There was a significant baseline severity by treatment interaction for HAM-D17 total score only (P = 0.027), with a larger treatment effect for the severely depressed group.

IMPLICATIONS

Desvenlafaxine significantly improved depressive symptoms in patients younger than 65 years and in patients with moderate or severe baseline depression. Sample sizes were not adequate to assess desvenlafaxine efficacy in patients 65 years or older or with mild baseline depression.